Received May 8, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 2 | X0005836 | SC / RA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | N/A | 3CB9L | IM / RL |
| YF | YELLOW FEVER (YF-VAX) | SANOFI PASTEUR | N/A | UJ830AC | SC / LA |
The patient was administered the one-vial preparation of MenVeo instead of the intended two-vial preparation. No adverse events were observed or reported following administration. Upon identification of the variance, the event was documented and the care team was notified.
unknown
unknown
unknown
none
none